---
title: "Compass Pathways publishes investor deck on COMP360 psilocybin therapy for treatment-resistant depression approval path"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291930081.md"
description: "Compass Pathways released an investor deck highlighting three statistically significant late-stage trials for COMP360 psilocybin therapy in treatment-resistant depression, supporting a rolling US NDA. Phase 3 trials COMP005 and COMP006 met primary endpoints with P"
datetime: "2026-07-07T12:08:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291930081.md)
  - [en](https://longbridge.com/en/news/291930081.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291930081.md)
---

# Compass Pathways publishes investor deck on COMP360 psilocybin therapy for treatment-resistant depression approval path

-   Compass Pathways highlighted three statistically significant late-stage TRD trials in more than 1,000 participants, supporting a rolling US NDA for COMP360. \* Phase 3 COMP005 and COMP006 met primary endpoints on MADRS change at Week 6, each reported at P<0.001. \* COMP006 showed 39% of 25 mg patients achieved a greater than 25% MADRS reduction at Week 6, with average response maintained through Week 26. \* COMP005 reported 25% of 25 mg patients achieved that threshold at Week 6, with average response maintained through Week 26. \* Launch planning targeted end-2026 readiness, with a first-half 2027 launch timeline contingent on FDA clearance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)

## Related News & Research

- [CMPS: COMP360 targets a 2027 launch, offering rapid, durable relief for TRD and advancing a PTSD program](https://longbridge.com/en/news/295675963.md)
- [Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plans](https://longbridge.com/en/news/294963906.md)
- [Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia](https://longbridge.com/en/news/296228796.md)
- [Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy](https://longbridge.com/en/news/295558678.md)
- [08:51 ETFannin Receives CDMRP and Faris Foundation Grants to Advance Targeted RapDC Therapy for Ewing Sarcoma](https://longbridge.com/en/news/295937692.md)